Oncology Today with Dr Neil Love

Featuring an interview with Dr Jamie E Chaft, including the following topics:
Case: A man in his early 70s with a 40 to 50 pack-year history of smoking and cT2bN1 squamous cell carcinoma of the lung with PD-L1 60% treated with induction therapy and surgery (00:00)
Available clinical data with immunotherapy in the neoadjuvant, perioperative and adjuvant settings (07:45)
Factors in the selection of adjuvant immunotherapy, including circulating tumor DNA (11:39)
Evolving approaches to management, including systemic therapy, surgery and radiation therapy techniques (19:28)
Case: A woman in her early 60s with nonmetastatic non-small cell lung cancer (NSCLC) and an EGFR exon 19 deletion who is enrolled in the NeoADAURA study (24:03)
Importance of clinical trials in the adjuvant setting (33:02)
Data surrounding treatment in the neoadjuvant setting; key implications of the NeoADAURA study (35:41)
Case: A man in his late 60s with a history of smoking and Stage III T4N3 NSCLC not otherwise specified with low PD-L1 expression, high tumor mutation burden, microsatellite stability and an STK11 mutation (41:34)
Selecting patients for the NeoADAURA study treatment approach; deciding between chemoimmunotherapy and chemoradiation therapy (51:01)

CME information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics:
Case: A woman in her late 70s with de novo metastatic mismatch repair-proficient metastatic endometrioid endometrial cancer (00:00)
Molecular analyses in the assessment and management of endometrial cancer (07:33)

CME information and select publications

Featuring perspectives from Dr Christopher Flowers, Dr Matthew Lunning, Dr Sonali M Smith and Dr Brad S Kahl, moderated by Dr Kahl, including the following topics:
Rational Incorporation of CD79b-Targeted Antibody-Drug Conjugates into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Flowers (00:00)
Clinical Utility of CD19-Directed Monoclonal Antibodies in the Treatment of DLBCL and Follicular Lymphoma (FL) — Dr Smith (31:41)
Optimal Use of CD19-Directed Antibody-Drug Conjugates for R/R DLBCL and FL — Dr Lunning (01:03:23)
Current and Future Role of Bruton Tyrosine Kinase Inhibition in Therapy for Non-Hodgkin Lymphoma — Dr Kahl (01:26:48)

CME information an d select publications

Featuring perspectives from Prof Giuseppe Curigliano, Prof Rebecca A Dent, Dr Erika Hamilton, Prof Nadia Harbeck and Dr Hope S Rugo, moderated by Dr Rugo, including the following topics:
Introduction (00:00)
Evolving Role of Antibody-Drug Conjugates (ADCs) in the Management of Metastatic Triple-Negative Breast Cancer — Prof Dent (02:57)
Integrating ADCs into the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Prof Curigliano (29:01)
Role of ADCs in the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Rugo (52:36)
Emerging Utility of ADCs for Localized Breast Cancer — Prof Harbeck (01:14:36)
Tolerability Considerations with ADCs for Breast Cancer — Dr Hamilton (01:38:10)

CME information and select publications

Featuring an interview with Dr Floor J Backes, including the following topics:
Overview of the treatment landscape of endometrial cancer (00:00)
Immunotherapy for advanced endometrial cancer (03:58)
Contraindications for immunotherapy (18:15)
PARP inhibitors for endometrial cancer (20:12)
Management of localized endometrial cancer (28:23)
Novel strategies under investigation for endometrial cancer (42:27)

CME information and select publications